[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ATE513929T1 - Gene mit einfluss auf die menschliche gedächtnisleistung - Google Patents

Gene mit einfluss auf die menschliche gedächtnisleistung

Info

Publication number
ATE513929T1
ATE513929T1 AT07777651T AT07777651T ATE513929T1 AT E513929 T1 ATE513929 T1 AT E513929T1 AT 07777651 T AT07777651 T AT 07777651T AT 07777651 T AT07777651 T AT 07777651T AT E513929 T1 ATE513929 T1 AT E513929T1
Authority
AT
Austria
Prior art keywords
human memory
affecting human
memory performance
genes affecting
diseases
Prior art date
Application number
AT07777651T
Other languages
English (en)
Inventor
Andreas Papassotiropoulos
Dietrich Stephan
Quervain Dominique De
Original Assignee
Translational Genomics Res Inst
Univ Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Translational Genomics Res Inst, Univ Zuerich filed Critical Translational Genomics Res Inst
Application granted granted Critical
Publication of ATE513929T1 publication Critical patent/ATE513929T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/172Haplotypes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT07777651T 2006-01-27 2007-01-26 Gene mit einfluss auf die menschliche gedächtnisleistung ATE513929T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US76271306P 2006-01-27 2006-01-27
US86219406P 2006-10-19 2006-10-19
PCT/US2007/061112 WO2007120955A2 (en) 2006-01-27 2007-01-26 Genes affecting human memory performance

Publications (1)

Publication Number Publication Date
ATE513929T1 true ATE513929T1 (de) 2011-07-15

Family

ID=38610268

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07777651T ATE513929T1 (de) 2006-01-27 2007-01-26 Gene mit einfluss auf die menschliche gedächtnisleistung

Country Status (7)

Country Link
US (1) US7993836B2 (de)
EP (1) EP1987165B1 (de)
JP (1) JP5191906B2 (de)
AT (1) ATE513929T1 (de)
AU (1) AU2007238541A1 (de)
CA (1) CA2638802A1 (de)
WO (1) WO2007120955A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008019395A2 (en) * 2006-08-10 2008-02-14 Translational Genomics Research Institute Compounds for improving learning and memory
TW201030337A (en) * 2009-02-04 2010-08-16 Tzu Chi Buddhist General Hospital Method and kit for detecting cancers
EP2354789A1 (de) 2010-02-08 2011-08-10 Sygnis Bioscience GmbH & Co. KG Verfahren zur Identifizierung von gedächtnismodulierenden Verbindungen durch Auswertung der KIBRA-Expression
WO2013041239A1 (en) * 2011-09-21 2013-03-28 Sygnis Bioscience Gmbh & Co. Kg Pkm zeta bindin peptides, peptide derivatives and conjugates, and uses thereof
WO2013041238A1 (en) * 2011-09-21 2013-03-28 Sygnis Bioscience Gmbh & Co. Kg Use of kibra peptides, hdac inhibitor or proteasome inhibitor for improving anxiety disorders
CN116925205A (zh) * 2022-04-07 2023-10-24 复旦大学 激活Hippo信号通路的多肽及其用途
CN114457154B (zh) * 2022-04-13 2022-06-28 山东第一医科大学附属省立医院(山东省立医院) KIBRA rs17070145检测试剂在制备嗅觉功能评价试剂盒中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5993054A (ja) * 1982-11-18 1984-05-29 Asahi Chem Ind Co Ltd イソキノリンスルホン酸アミド誘導体
US4678783B1 (en) * 1983-11-04 1995-04-04 Asahi Chemical Ind Substituted isoquinolinesulfonyl compounds
DE3583287D1 (de) 1984-12-27 1991-07-25 Asahi Chemical Ind Substituierte isochinolinsulfonyl-verbindungen.
JPH0667926B2 (ja) * 1985-11-12 1994-08-31 旭化成工業株式会社 環状のイソキノリンスルホンアミド誘導体
JP3464012B2 (ja) 1993-04-05 2003-11-05 旭化成株式会社 精神症候治療剤
KR100236853B1 (ko) * 1995-07-03 2000-02-01 야마모토 카즈모토 1-(5-이소퀴놀린술포닐)호모피페라진 염산염 수화물
EP1110553B1 (de) * 1998-08-10 2013-03-27 Asahi Kasei Pharma Corporation Orale zusammensetzungen zur kontrollierten freisetzung von fasudil hydrochlorid
ZA200302044B (en) 2000-09-14 2004-03-15 Univ Zuerich Calcium binding proteins.
CA2533803A1 (en) * 2003-07-29 2005-02-10 Bristol-Myers Squibb Company Biomarkers of cyclin-dependent kinase modulation
KR100565056B1 (ko) 2003-08-14 2006-03-30 삼성전자주식회사 Av 데이터를 enav 모드로 재생하는 방법, 그 장치및 그 정보저장매체
WO2008019395A2 (en) * 2006-08-10 2008-02-14 Translational Genomics Research Institute Compounds for improving learning and memory

Also Published As

Publication number Publication date
AU2007238541A1 (en) 2007-10-25
EP1987165A4 (de) 2010-01-27
JP5191906B2 (ja) 2013-05-08
US20090227500A1 (en) 2009-09-10
WO2007120955A3 (en) 2008-02-14
WO2007120955A2 (en) 2007-10-25
US7993836B2 (en) 2011-08-09
EP1987165B1 (de) 2011-06-22
JP2009524437A (ja) 2009-07-02
EP1987165A2 (de) 2008-11-05
CA2638802A1 (en) 2007-10-25

Similar Documents

Publication Publication Date Title
MX2009012722A (es) Variantes geneticas sobre chr 5p12 y 10q26 como marcadores para el uso en la evaluacion del riesgo, diagnostico, pronostico y tratamiento del cancer de mama.
EA200800087A1 (ru) Генетические варианты гена tcf7l2 как диагностические маркеры риска возникновения сахарного диабета ii типа
ATE526991T1 (de) Zusammensetzungen und ihre verwendungen für die gentherapeutische behandlung von knochenerkrankungen
WO2004066941A3 (en) Expression profiles for colon cancer and methods of use
ATE513929T1 (de) Gene mit einfluss auf die menschliche gedächtnisleistung
EA201590833A1 (ru) Антитела для лечения и профилактики болезни альцгеймера и их применение
CR9315A (es) Metodos y sistemas para el diagnostico, pronostico y seleccion del tratamiento de la leucemia
EA200970891A1 (ru) Генетические варианты chr2 и chr16 в качестве маркеров для применения при оценке риска, диагностировании, прогнозировании и лечении рака молочной железы
HN2008000346A (es) Secuencias de nucleotidos que codifican proteinas insecticidas
NO20092023L (no) Oligoribonuleotider og anvendelser derav
WO2010062960A3 (en) METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE
WO2010004591A3 (en) Genetic variants for breast cancer risk assessment
WO2005059108A3 (en) Gene expression profiles and methods of use
WO2007058968A3 (en) Gene expression profiles and methods of use
MX2010001993A (es) Metodos y composiciones para diagnosticar una enfermedad.
ATE534738T1 (de) Mir-126-regulierte gene und pfade als ziele für therapeutische interventionen
WO2004078035A3 (en) Expression profiles for breast cancer and methods of use
EP2423684A3 (de) Profilbestimmungsanalyse der differentiellen Expression von Zellkulturph. und Verwendung damit
TW200716132A (en) Novel chemical compounds
DE60302350D1 (de) Verwendung von adenoviren mit mutationen in den va-genen für die krebstherapie
ATE446385T1 (de) Polymorphismen im nod2/card15 gen
NO20021147D0 (no) Polymorfismer i det humane hPXR-genet og deres anvendelse i diagnostiske og terapeutiske applikasjoner
NO20052956D0 (no) Defensinprotiner
TW200716579A (en) Novel chemical compounds
ATE533861T1 (de) Mipol1-etv1-gen-neuanordnungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1987165

Country of ref document: EP